Latest News and Press Releases

STOCKHOLM, Sweden, May 23, 2006 (PRIMEZONE) -- Diamyd Medical AB (Other OTC:DMYDF) (Stockholm:DIAMB) announced today that results from studies with the Diamyd(tm) therapeutic for autoimmune diabetes...

STOCKHOLM, Sweden, May 12, 2006 (PRIMEZONE) -- Diamyd Medical AB (Stockholm:DIAMB) (Other OTC:DMYDF) with its lead drug candidate for diabetes in Phase IIb trials, announced today that Khandaker...

STOCKHOLM, Sweden, April 20, 2006 (PRIMEZONE) -- Diamyd Medical AB (Other OTC:DMYDF), a biotechnology company focused on the treatment of diabetes and its complications, including chronic pain and...

STOCKHOLM, Sweden, April 19, 2006 (PRIMEZONE) -- Diamyd Medical AB (Other OTC:DMYDF) (OMX:DIAMB), a biotechnology company focused on the treatment of diabetes and its complications today announced...

STOCKHOLD, Sweden, March 28, 2006 (PRIMEZONE) -- Diamyd Medical AB (Other OTC:DMYDF) (OMX:DIAMB), along with local institutions, will sponsor the first Seattle-Sweden Childhood Diabetes Awareness Day...

STOCKHOLM, Sweden, Jan. 20, 2006 (PRIMEZONE) -- Diamyd Medical AB (Pink Sheets:DMYDF), a global biotechnology company focused on the treatment of diabetes and its complications, including chronic pain...

STOCKHOLM, Sweden, Dec. 19, 2005 (PRIMEZONE) -- Diamyd Medical AB (OMX:DIAMB) today announced that is has reached an agreement with Protein Sciences Corporation, a Meriden, CT-based biopharmaceutical...

STOCKHOLM, Sweden, Dec. 15, 2005 (PRIMEZONE) -- Diamyd Medical AB (OMX:DIAMB) today announced the successful results of a pre-clinical study demonstrating the safety and tolerability of a novel...

STOCKHOLM, Sweden, Dec. 13, 2005 (PRIMEZONE) -- Diamyd Medical AB (OMX:DIAMB) emerged as a global biotechnology company as shareholders approved the acquisition of Nurel Therapeutics, Inc. at a...

STOCKHOLM, Sweden, Nov. 22, 2005 (PRIMEZONE) -- Diamyd Medical AB (OMX:DIAMB), today announced that it has agreed to acquire all of the outstanding shares in Nurel, a Pittsburgh, PA-based...